Over the past six months, Abbott Laboratories’s shares (currently trading at $125.45) have posted a disappointing 7.9% loss, ...

Abbott Laboratories (NYSE:ABT) is scheduled to announce its second-quarter earnings on Thursday, July 17, 2025. For traders who focus on events, examining the historical reactions of the stock to ...

Buy Abbott: defensive compounder with recurring cash flow. Libre diabetes devices drive growth; 2025 guidance reaffirmed.

Abbott (NYSE: ABT) will report its Q2 2024 results on Thursday, July 18. We expect the company to post revenue of $10.3 billion and earnings of $1.10 on a per share and adjusted basis, broadly ...

Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Abbott (ABT). But which of these two stocks offers value investors a ...

On Dec. 24, Teva Pharmaceutical announced that S&P Global Ratings has upgraded Teva’s long-term issuer credit rating to ‘BB+’ ...

Investors focused on the Medical space have likely heard of Abbott Laboratories (ABT), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this ...

It is hard to get excited after looking at Abbott Laboratories' (NYSE:ABT) recent performance, when its stock has declined ...

$ABT insiders have traded $ABT stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales. We have seen 1,192 ...

On December 22, Abbott Laboratories (NYSE:ABT) said the US Food and Drug Administration has approved the company’s Volt™ PFA ...

Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their ...